1.. Introduction {#S1}
================

Colorectal cancer was the third most common cancer (1653476 new cases, 9.5% of the total new cancer cases) and was the second leading cause of cancer deaths (832000 deaths, 9.5% of the total cancer deaths) in the world in 2015 \[[@R1]\].

Type 2 diabetes mellitus has been found to be a risk factor for colorectal cancer \[[@R2]\]. Thiazolidinediones are widely used for the treatment of type 2 diabetes mellitus \[[@R3]\]. *In vitro* and animal studies have found that thiazolidinediones have anti-tumor effects \[[@R4]--[@R6]\]. Observational studies have found that thiazolidinediones use correlates with a reduced risk of cancer \[[@R7]--[@R9]\].

Colorectal cancer ranked the third leading cause of cancer death in Taiwan in 2016, and Diabetes mellitus was the fifth leading cause of death in Taiwan in 2016 \[[@R10]\]. To date, data on the association between thiazolidinediones use and colorectal cancer in Taiwan are limited. Therefore, we conducted a population-based case-control study using the database of the Taiwan National Health Insurance (NHI) Program to assess whether there was an association between colorectal cancer and thiazolidinediones use.

2.. Methods {#S2}
===========

2.1.. Study design and data source {#S3}
----------------------------------

We conducted a population-based case-control study utilizing the claims data of the Taiwan National Health Insurance Program. The program was launched in March 1, 1995, and it covers about 99.6% of 23 million residents living in the independent country of Taiwan \[[@R11]--[@R17]\]. The study design, data source, and program details were adapted from previous studies \[[@R18]--[@R21]\].

2.2.. Study subjects {#S4}
--------------------

The case group consisted of type 2 diabetic subjects aged 20 to 84 years with newly diagnosed colorectal cancer between 2000 and 2011 (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 codes 153 and 154). The date of a subject being diagnosed with colorectal cancer was defined as the index date. The control group consisted of randomly selected type 2 diabetic subjects aged 20 to 84 years without colorectal cancer between 2000 and 2011. Subjects who had any other cancer (ICD-9 codes 140-208) before their index date were excluded from the study.

2.3.. Comorbidities studied {#S5}
---------------------------

We selected comorbidities before the index date as follows: alcohol-related disease, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, colorectal adenoma, hyperlipidemia, hypertension, inflammatory bowel disease, as well as chronic liver diseases including cirrhosis, hepatitis B infection, hepatitis C infection, and other chronic hepatitis. All comorbidities were selected based on ICD-9 codes, which have been carefully validated in previous studies \[[@R22]--[@R29]\].

2.4.. Definition of thiazolidinediones use and other anti-diabetic drugs use {#S6}
----------------------------------------------------------------------------

The thiazolidinediones on the Taiwan market during 2000-2011 were pioglitazone and rosiglitazone. Other anti-diabetic drugs on the Taiwan market during 2000-2011 were metformin, sulfo- nylureas, a-glucosidase inhibitors, DPP-4 inhibitors, and insulins. The prescription histories of the medications studied were collected. The definition of medication use was adapted from previous studies \[[@R30]-[@R40]\]. A subject who had at least a prescription of medications studied before the index date was defined as "ever used". A subject who did not have a prescription of medications studied before the index date was defined as "never used".

2.5.. Statistical analysis {#S7}
--------------------------

First, we examined the distributions of sex, age, thiazolidin- ediones use, other anti-diabetic drugs use, and comorbidities between the case group and the control group using a *Chi-square* test for categorized variables and using a f-test for continuous variables. Second, variables which were statistically associated with colorectal cancer in a univariable logistic regression model were further included in a multivariable logistic regression model. The odds ratio (OR) and 95% confidence interval (CI) was used to estimate the association between colorectal cancer and thiazoli- dinediones use. Third, the association between colorectal cancer and cumulative duration of thiazolidinediones use was also estimated. Fourth, all analyses were performed using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, North Carolina, USA), and the results were considered statistically significant when two-tailed *P* values were \< 0.05.

3.. Results {#S8}
===========

3.1.. Basic characteristics of the study population {#S9}
---------------------------------------------------

[Table 1](#T1){ref-type="table"} disclosed that there were 20218 type 2 diabetic subjects with colorectal cancer in the case group and 20218 type 2 diabetic subjects without colorectal cancer in the control group. The case group and the control group had similar distributions of sex and age. The mean ages (standard deviation) were 68.2 (9.7) years in the case group and 68.1 (9.6) years in the control group, without statistical significance (f-test, *P* = 0.39). The case group had higher proportions of other anti-diabetic drugs use (86.8% vs. 83.2%) and alcohol-related disease (5.69% vs. 4.97%) than the control group, with statistical significance (*Chi*-square test, *P* \< 0.001 and *P* = 0.001, respectively). There were no statistical differences of thiazolidinediones use and other comorbidities between the case group and the control group (*Chi*-square test, *P* \> 0.05 for all). Table 1Characteristics between cases with colorectal cancer and controls.Controls N = 20218Cases with colorectal cancer N = 20218Variablen(%)n(%)P value[\*](#TFN1){ref-type="table-fn"}Sex0.10 Female9059(44.8)8897(44.0) Male11159(55.2)11321(56.0)Age group (years)0.53 20-39110(0.5)115(0.6) 40-646777(33.5)6877(34.0) 65-8413331(66.0)13226(65.4)Age (years), mean ± standard deviation[†](#TFN2){ref-type="table-fn"}68.1 ± 9.668.2 ± 9.70.39 Thiazolidinediones use3818(18.9)3787(18.7)0.69 Other anti-diabetic drugs use16816(83.2)17546(86.8)\< 0.001Comorbidities before index date Alcohol-related disease1004(4.97)1151(5.69)0.001 Cardiovascular disease11475(56.8)11333(56.1)0.15 Chronic kidney disease3012(14.9)3015(14.9)0.97 Chronic liver diseases5187(25.7)5286(26.2)0.26 Chronic obstructive pulmonary disease5459(27.0)5469(27.1)0.91 Colorectal adenoma338(1.67)376(1.86)0.15 Hyperlipidemia11256(55.7)11222(55.5)0.73 Hypertension15914(78.7)15814(78.2)0.23 Inflammatory bowel disease329(1.63)375(185)0.08Data are presented as the number of subjects in each group with percentages given in parentheses.[^1][^2]

3.2.. Association between colorectal cancer and thiazolidin- ediones use {#S10}
------------------------------------------------------------------------

After adjustment for potential confounders, the multivariable logistic regression model disclosed that the odds of thiazolidin- ediones use in cases with colorectal cancer were lower than the odds of thiazolidinediones use in subjects without colorectal cancer (adjusted OR 0.94, 95% CI 0.89-0.99; [Table 2](#T2){ref-type="table"}). In addition, use of other anti-diabetic drugs (adjusted OR 1.35, 95% CI 1.27-1.42), and alcohol-related disease (adjusted OR 1.15, 95% CI 1.06-1.26) were other factors statistically associated with colorectal cancer.Table 2Odds ratio and 95% confidence interval of thiazolidinediones cancer by multivariable logistical regression model.CrudeAdjusted[†](#TFN3){ref-type="table-fn"}VariableOR(95% CI)OR(95% CI)Sex (male vs. female)1.03(0.99, 1.07)Age (per one year)1.00(0.99, 1.003)Thiazolidinediones use (never used as a reference)0.99(0.94, 1 .04)0.94(0.89, 0.99)Other anti-diabetic drugs use (never used as a reference)1.33(1.26, 1.40)1.35(1.27, 1.42)Comorbidities before index date (yes vs. no) Alcohol-related disease1.16(1.06, 1.26)1.15(1.06, 1.26) Cardiovascular disease0.97(0.93, 1.01) Chronic kidney disease1.00(0.95, 1.06) Chronic liver diseases1.03(0.98, 1.07) Chronic obstructive pulmonary disease1.003(0.96, 1.05) Colorectal adenoma1.11(0.96, 1.29) Hyperlipidemia0.99(0.96, 1.03) Hypertension0.97(0.93, 1.02) Inflammatory bowel disease1.14(0.98, 1.33)[^3]

3.3.. Association between colorectal cancer and cumulative duration of thiazolidinediones use {#S11}
---------------------------------------------------------------------------------------------

After adjustment for potential confounders, the odds of thiazoli- dinediones use for every one year in cases with colorectal cancer were lower than subjects without colorectal cancer (adjusted OR 0.998, 95% CI 0.997-0.999; [Table 3](#T3){ref-type="table"}).Table 3Odds ratio and 95% confidence interval of cumulative duration of thiazolidinediones use associated with colorectal cancer.VariableCase number /control numberCrude OR(95% CI)Adjusted OR[†](#TFN4){ref-type="table-fn"}(95% CI)Never used thiazolidinediones as a reference16431/164001.00(reference)1.00(reference)Cumulative duration of thiazolidinediones use (increase every one year)3787/38181.00(0.99, 1.001)0.998(0.997, 0.999)[^4]

4.. Discussion {#S12}
==============

In this case-control study, we noted that the odds of thiazoli- dinediones use in cases with colorectal cancer were lower than subjects without colorectal cancer (adjusted OR 0.94, [Table 2](#T2){ref-type="table"}). In addition, we noted that the odds of thiazolidinediones use for every one year in cases with colorectal cancer were lower than subjects without colorectal cancer (adjusted OR 0.998, [Table 3](#T3){ref-type="table"}). The sub-analysis disclosed that the odds of cumulative duration of thiazolidinediones use \> 1 year in cases with colorectal cancer were lower than subjects without colorectal cancer (adjusted OR 0.92, 95% CI 0.86-0.99). These findings suggest that there is a duration-dependent manner of thiazolidinediones use on the risk reduction of colorectal cancer. That is, the protective effect on colorectal cancer was greater for the longer duration of thiazolidinediones use. Our findings are compatible with prior studies reporting that patients with type 2 diabetes mellitus using thiazolidinediones had a lower risk of colorectal cancer.\[[@R7], [@R8]\] This means that thiazolidinediones use might have a potentially protective effect on the risk of colorectal cancer.

Although the mechanisms affecting the association between thiazolidinediones use and the reduced risk of colorectal cancer cannot be disclosed in an observational study, we summarize the current literature as follows. Four main pathways are involved in the anti-tumor actions of thiazolidinediones: (1) inhibition of cell proliferation, (2) inhibition of cell growth, (3) inhibition of cell invasion, and (4) induction of cell apoptosis \[[@R4]-[@R7], [@R41]\]. These pathways partially explain why thiazolidinediones use is associated with a risk reduction of colorectal cancer.

4.1.. Limitation and Strength {#S13}
-----------------------------

The causal relationship cannot be disclosed in a case-control study. A prospective study is required to test the clear-cut causal relationship between thiazolidinediones use and the risk of colorectal cancer. Nevertheless, this topic is interesting. The manuscript is well prepared and each step has been clearly presented. The manuscript is suitable for the readers of Biomedicine.

5.. Conclusion {#S14}
==============

We conclude that the odds of thiazolidinediones use in cases with colorectal cancer are lower than subjects without colorectal cancer. A prospective study is required to test whether thiazolidin- ediones use has a protective effect against colorectal cancer.
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[^1]: *Chi*-square test, and

[^2]: *t*-test comparing cases with colorectal cancer and controls.

[^3]: Variables which were statistically associated with colorectal cancer in a univariable model were further included in a multivariable model. Only other anti-diabetic drugs and alcohol-related disease were included for adjustment.

[^4]: Variables which were statistically associated with colorectal cancer in a univariable model were further included in a multivariable model. Only other anti-diabetic drugs and alcohol-related disease were included for adjustment.
